112 related articles for article (PubMed ID: 20682177)
1. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer.
Ghafouri-Fard S; Ousati Ashtiani Z; Sabah Golian B; Hasheminasab SM; Modarressi MH
Arch Med Res; 2010 Apr; 41(3):195-200. PubMed ID: 20682177
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features.
Ghafouri-Fard S; Abbasi A; Moslehi H; Faramarzi N; Taba Taba Vakili S; Mobasheri MB; Modarressi MH
Br J Dermatol; 2010 Apr; 162(4):772-9. PubMed ID: 19886887
[TBL] [Abstract][Full Text] [Related]
3. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
6. Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.
Wong KK; Hussain FA; Loo SK; López JI
APMIS; 2017 Dec; 125(12):1092-1101. PubMed ID: 28972294
[TBL] [Abstract][Full Text] [Related]
7. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
8. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
11. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
12. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.
Sidiropoulos M; Chang A; Jung K; Diamandis EP
Br J Cancer; 2001 Aug; 85(3):393-7. PubMed ID: 11487271
[TBL] [Abstract][Full Text] [Related]
13. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
14. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members.
Gjerstorff MF; Ditzel HJ
Tissue Antigens; 2008 Mar; 71(3):187-92. PubMed ID: 18179644
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
16. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer.
Kosari F; Asmann YW; Cheville JC; Vasmatzis G
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1419-26. PubMed ID: 12433721
[TBL] [Abstract][Full Text] [Related]
17. Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient.
Ghafouri-Fard S; Ghafouri-Fard S; Modarressi MH
Genet Mol Res; 2012 Oct; 11(4):3642-8. PubMed ID: 23096689
[TBL] [Abstract][Full Text] [Related]
18. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
19. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
